Skip to content
2000
Volume 16, Issue 4
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

The conserved cylindromatosis (CYLD) codes for a deubiquitinating enzyme and is a crucial regulator of diverse cellular processes such as immune responses, inflammation, death, and proliferation. It directly regulates multiple key signaling cascades, such as the Nuclear Factor kappa B [NFkB] and the Mitogen-Activated Protein Kinase (MAPK) pathways, by its catalytic activity on polyubiquitinated key intermediates. Several lines of emerging evidence have linked CYLD to the pathogenesis of various maladies, including cancer, poor infection control, lung fibrosis, neural development, and now cardiovascular dysfunction. While CYLD-mediated signaling is cell type and stimuli specific, the activity of CYLD is tightly controlled by phosphorylation and other regulators such as Snail. This review explores a broad selection of current and past literature regarding CYLD’s expression, function and regulation with emerging reports on its role in cardiovascular disease.

Loading

Article metrics loading...

/content/journals/cdt/10.2174/1389450115666141024152421
2015-04-01
2025-05-21
Loading full text...

Full text loading...

/content/journals/cdt/10.2174/1389450115666141024152421
Loading

  • Article Type:
    Research Article
Keyword(s): Cardiovascular; CYLD; cylindromatosis; deubiquitination; K63; MAPK; NF-kB
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test